OBJECTIVE: To systematically evaluate the clinical efficacy of compound glycyrrhizin in the treatment of fatty liver. METHODS: PubMed

the Cochrane Library

Embase

CNKI

Wanfang Data and VIP database were retrieved to collect the randomized controlled trials（RCT） of compound glycyrrhizin in the treatment of fatty liver（the study group was treated with compound glycyrrhizin + other treatments

while the control group received other treatments except for compound glycyrrhizin） till Nov. 2021. Meta-analysis was performed by using RevMan 5.3 software. RESULTS: Nine articles with a total of 795 patients were extracted

including 400 cases in the study group and 395 cases in the control group. Meta-analysis results showed that the clinical effective rate in the study group was significantly higher than that in the control group（OR=6.35

95%CI=4.00-10.07

Z=7.85

P<0.000 01）

AST（MD=-31.88

95%CI=-51.14--12.62

Z=3.24

P=0.001）

ALT（non-alcoholic fatty liver disease subgroup: MD=-14.68

95%CI=-18.15--11.22

Z=8.30

P<0.000 01; alcoholic fatty liver disease subgroup: MD=-29.52

95%CI=-30.77--28.28

Z=46.36

P<0.000 01） and TG（MD=-0.73

95%CI=-1.19--0.27

Z=3.10

P=0.002） were significantly lower than those in the control group

the differences were statistically significant. There was no statistical significance in the incidence of adverse drug reactions between two groups（OR=0.38

95%CI=0.14-1.03

Z=1.91

P=0.06>0.05）. CONCLUSIONS: Compound glycyrrhizin has better efficacy and higher safety in the treatment of fatty liver.